[Introduction] Sepsis is a pathological condition in which organ dysfunction progresses due to infection. The international definition of sepsis was changed in 2016, and it is managed as Sepsis-3. Infectious diseases exacerbate organ dysfunction and immunodeficiency as a second attack in cancer, stroke, acute myocardial infarction, diabetes and mental disorders. On the other side, septic shock is a condition in which sepsis is accompanied by cardiovascular disorders, and is classified as a severe condition in sepsis. The management and drug discovery against sepsis and septic shock is required in an area of intensive care medicine and pharmacology. In this symposium, we will discuss and review the current definition and scientific approaches, and the pathophysiological characteristics of sepsis and septic shock, We will discuss the drug discovery science against sepsis/septic shock from a pharmacological perspective.
[Contents] 1. Current definition of sepsis and the World Health Organization activity, 2. Molecular pharmacological approach on septic shock: Pathophysiology of septic heart injury, 3. Accelerated cell death in sepsis, 4. Molecular pharmacological involvement in drug discovery against sepsis/septic shock.
[Conclusion] In the pathophysiological approach to sepsis, various transcription factors are activated and related with the catabolism of proteins and lipids and accelerated cell death. We will discuss the possibility of new drug discovery against sepsis and septic shock.